These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20304062)

  • 41. Expression of proteinase-activated receptor-2 (PAR2) is androgen-dependent in stromal cell line (hPCPs) from benign prostatic hyperplasia.
    Mannowetz N; Würdinger R; Zippel A; Aumüller G; Wennemuth G
    Prostate; 2010 Sep; 70(12):1350-8. PubMed ID: 20623639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Role of bFGF and TGF-beta1 in primary cultured prostatic stromal cells].
    Gu H; Dong ZX; Wang CB; Yuan YF; Hou JH
    Zhonghua Nan Ke Xue; 2006 Oct; 12(10):917-22. PubMed ID: 17121024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ultrastructural changes in prostate cells during hormone-induced canine prostatic hyperplasia.
    Gallardo-Arrieta F; Mogas T; Magán L; García MA; García F; Abal M; Morote J; Serrano S; Reventós J; Lioreta J
    Ultrastruct Pathol; 2006; 30(6):435-42. PubMed ID: 17182436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermediate-conductance Ca2+-activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia.
    Ohya S; Niwa S; Kojima Y; Sasaki S; Sakuragi M; Kohri K; Imaizumi Y
    J Pharmacol Exp Ther; 2011 Aug; 338(2):528-36. PubMed ID: 21602424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of fluorines on nonsecosteroidal vitamin D receptor agonists.
    Kashiwagi H; Ohta M; Ono Y; Morikami K; Itoh S; Sato H; Takahashi T
    Bioorg Med Chem; 2013 Feb; 21(3):712-21. PubMed ID: 23266184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen.
    Ho CK; Nanda J; Chapman KE; Habib FK
    J Endocrinol; 2008 Jun; 197(3):483-91. PubMed ID: 18492814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stromal cells of the human prostate: initial isolation and characterization.
    Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
    Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
    Murakoshi M; Ikada R; Tagawa M; Nakayama T
    Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human bladder as a novel target for vitamin D receptor ligands.
    Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
    J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An investigation on the relevance of prolactin, insulin-like growth factor-1 and 25-hydroxyvitamin D
    Werhahn Beining F; Schmicke M; Wilkens M; Wolf K; Rohn K; Günzel-Apel AR
    Vet Med Sci; 2021 Sep; 7(5):1493-1503. PubMed ID: 34015193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia.
    Manchanda PK; Kibler AJ; Zhang M; Ravi J; Bid HK
    Indian J Urol; 2012 Oct; 28(4):377-81. PubMed ID: 23450267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
    Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
    Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
    J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
    Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
    Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
    Taniguchi K; Katagiri K; Kashiwagi H; Harada S; Sugimoto Y; Shimizu Y; Arakawa H; Ito T; Yamazaki M; Watanabe T; Kato A; Hoshino E; Takahashi T; Esaki T; Suzuki M; Takeda S; Ichikawa F; Harada A; Sekiguchi N; Ishigai M; Kawata H; Yoneya T; Onuma E; Sudoh M; Aoki Y
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):204-7. PubMed ID: 20304062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.
    Kashiwagi H; Ono Y; Ohta M; Itoh S; Ichikawa F; Harada S; Takeda S; Sekiguchi N; Ishigai M; Takahashi T
    Bioorg Med Chem; 2013 Apr; 21(7):1823-33. PubMed ID: 23453218
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.